↓ Skip to main content

The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview

Overview of attention for article published in Drugs & Aging, August 2018
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
63 Mendeley
Title
The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview
Published in
Drugs & Aging, August 2018
DOI 10.1007/s40266-018-0574-y
Pubmed ID
Authors

Cheryl Phua, Rodney Baber

Abstract

The improved detection and successful treatment of breast cancer, resulting in better survival rates, has led to an increasing number of women living with the effects of treatment modalities and their long-term consequences. Menopausal symptoms following breast cancer can occur at an earlier age, be more severe and significantly influence a woman's overall wellbeing, in particular, sexual function, quality of life and adherence to treatment. There is a dearth of good quality evidence on the safest and most effective treatment options available for these women, and this article aims to summarize the current available treatments. Pertinent to these women is general advice, such as avoidance of triggers, and lifestyle modifications. Following which, non-pharmacological interventions, including cognitive behavior therapy (CBT), hypnosis, acupuncture, stellate ganglion nerve block and complementary agents, are discussed. Pharmacological therapies and their safety profile in these high-risk women are then examined; namely, menopausal hormone therapy, progestogens, antidepressants (selective serotonin reuptake inhibitors and selective noradrenaline reuptake inhibitors), gabapentin, clonidine and intra-vaginal dehydroepiandrosterone (DHEA). Finally, neurokinin 3 receptor antagonists, promising new agents for the treatment of troublesome menopausal vasomotor symptoms, are discussed.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 63 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 11 17%
Student > Master 7 11%
Researcher 6 10%
Other 4 6%
Student > Ph. D. Student 3 5%
Other 5 8%
Unknown 27 43%
Readers by discipline Count As %
Medicine and Dentistry 17 27%
Nursing and Health Professions 5 8%
Psychology 4 6%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Mathematics 1 2%
Other 5 8%
Unknown 29 46%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 August 2018.
All research outputs
#18,645,475
of 23,098,660 outputs
Outputs from Drugs & Aging
#1,063
of 1,218 outputs
Outputs of similar age
#254,520
of 331,034 outputs
Outputs of similar age from Drugs & Aging
#24
of 27 outputs
Altmetric has tracked 23,098,660 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,218 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one is in the 5th percentile – i.e., 5% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,034 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.